Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04665310
Recruitment Status : Withdrawn (Study not started, funding)
First Posted : December 11, 2020
Last Update Posted : December 11, 2020
Sponsor:
Collaborator:
Veloxis Pharmaceuticals
Information provided by (Responsible Party):
Ahmed Osama Gaber, MD, The Methodist Hospital System

Brief Summary:
In spite of conventional immunosuppression with lymphocyte-depleting induction followed by tacrolimus- and mycophenolate-based regimens, African American (AA) renal transplant recipients experience higher rates of acute rejection (AR), donor specific antibodies (DSA), and graft failure. Envarsus Extended-Release (XR)® (ENV) is a novel extended-release formulation of tacrolimus with a favorable pharmacokinetic profile, even in the setting of CYP3A5*1 allele (rapid metabolizers). The investigator will evaluate the safety and efficacy of early dose escalation with ENV in AA recipients. The study hypothesis is that higher tacrolimus target concentrations may be achieved without typical dose-limiting toxicities, and this may ultimately result in lower incidence of early AR, DSA, and graft loss.

Condition or disease Intervention/treatment Phase
Kidney Disease, End-Stage Donor Specific Antibodies Acute Rejection of Renal Transplant Drug: Envarsus XR Phase 4

Detailed Description:

Phase 4 (post-marketing) De novo African American living or deceased donor renal transplant recipients 18 to 65 years of age Number of subjects to be enrolled: 60

All patients will receive standard induction immunosuppression according to institution protocol. Within one week of transplantation, all patients will be converted from immediate-release tacrolimus (TAC) to extended-release tacrolimus (ENV) at 20% reduction in total daily dosage. Patients will be randomized to low-, moderate-, or high-intensity ENV groups, stratified by peak panel reactive antibody (pPRA) greater than or equal to 75%. Target tacrolimus trough concentrations for the first month post-transplant will be 8-10 ng/mL in low-intensity group, 10-12 ng/mL in moderate-intensity group, and 12-14 ng/mL in high-intensity group; likewise from month 1-3 post-transplant, target trough concentrations will be 6-8 ng/mL, 8-10 ng/mL, and 10-12 ng/mL, respectively. Subjects experiencing dose-limiting adverse events (AEs) will be de-escalated as warranted. Following month 3, all patients will be maintained on ENV at target tacrolimus trough concentrations according to institution protocol. Additional maintenance immunosuppression will consist of mycophenolate mofetil (MMF) at a goal dose of 2000 mg daily along with an oral prednisone taper to 5-10 mg daily by the end of month 1. All patients will be followed for 6 months post-transplant.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel Group - Dose Escalation with 2 groups stratified by pPRA <75% and >75% and then randomized into 3 Intensity Arms (Low, Moderate and High) based on dosing of Envarsus XR.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Early Dose Escalation Using Extended-Release Tacrolimus (Envarsus XR®) to Reduce Acute Rejection and Donor Specific Antibodies in African American Renal Transplant Recipients
Actual Study Start Date : September 1, 2018
Estimated Primary Completion Date : October 31, 2020
Estimated Study Completion Date : October 31, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Tacrolimus

Arm Intervention/treatment
Active Comparator: Group 1 - Low-Intensity

All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.

TAC dosing will be 2 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.

Target Tacrolimus Trough Concentrations:

Week 0 to Week 4: 8-10 mg/mL Month 1 to Month 3: 6-8 mg/mL

Drug: Envarsus XR
tacrolimus, extended-release tablets, a calcineurin inhibitor
Other Names:
  • Life Cycle Pharma (LCP)-tacrolimus
  • once-daily extended-release tacrolimus
  • once-daily prolonged-release tacrolimus
  • Tacrolimus-LCP

Active Comparator: Group 1 - Moderate-Intensity

All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.

TAC dosing will be 3 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.

Target Tacrolimus Trough Concentrations:

Week 0 to Week 4: 10-12 mg/mL Month 1 to Month 3: 8-10 mg/mL

Drug: Envarsus XR
tacrolimus, extended-release tablets, a calcineurin inhibitor
Other Names:
  • Life Cycle Pharma (LCP)-tacrolimus
  • once-daily extended-release tacrolimus
  • once-daily prolonged-release tacrolimus
  • Tacrolimus-LCP

Active Comparator: Group 1 - High-Intensity

All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.

TAC dosing will be 4 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.

Target Tacrolimus Trough Concentrations:

Week 0 to Week 4: 12-14 mg/mL Month 1 to Month 3: 10-12 mg/mL

Drug: Envarsus XR
tacrolimus, extended-release tablets, a calcineurin inhibitor
Other Names:
  • Life Cycle Pharma (LCP)-tacrolimus
  • once-daily extended-release tacrolimus
  • once-daily prolonged-release tacrolimus
  • Tacrolimus-LCP

Active Comparator: Group 2 - Low-Intensity

All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.

TAC dosing will be 2 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.

Target Tacrolimus Trough Concentrations:

Week 0 to Week 4: 8-10 mg/mL Month 1 to Month 3: 6-8 mg/mL

Drug: Envarsus XR
tacrolimus, extended-release tablets, a calcineurin inhibitor
Other Names:
  • Life Cycle Pharma (LCP)-tacrolimus
  • once-daily extended-release tacrolimus
  • once-daily prolonged-release tacrolimus
  • Tacrolimus-LCP

Active Comparator: Group 2 - Moderate-Intensity

All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.

TAC dosing will be 3 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.

Target Tacrolimus Trough Concentrations:

Week 0 to Week 4: 10-12 mg/mL Month 1 to Month 3: 8-10 mg/mL

Drug: Envarsus XR
tacrolimus, extended-release tablets, a calcineurin inhibitor
Other Names:
  • Life Cycle Pharma (LCP)-tacrolimus
  • once-daily extended-release tacrolimus
  • once-daily prolonged-release tacrolimus
  • Tacrolimus-LCP

Active Comparator: Group 2 - High-Intensity

All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.

TAC dosing will be 4 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.

Target Tacrolimus Trough Concentrations:

Week 0 to Week 4: 12-14 mg/mL Month 1 to Month 3: 10-12 mg/mL

Drug: Envarsus XR
tacrolimus, extended-release tablets, a calcineurin inhibitor
Other Names:
  • Life Cycle Pharma (LCP)-tacrolimus
  • once-daily extended-release tacrolimus
  • once-daily prolonged-release tacrolimus
  • Tacrolimus-LCP




Primary Outcome Measures :
  1. Number of participants reaching the composite endpoint [ Time Frame: 6 months ]
    Composite endpoint of freedom from all of the following: i) biopsy-proven T-cell mediated rejection Banff Grade ≥1A, ii) antibody-mediated rejection, iii) de novo DSA, or iv) immune-mediated graft loss. The endpoint is a binary endpoint (Yes or No) of the composite of all 4 potential outcomes. The presence of any one of the four possible outcomes will be counted as a No for the binary endpoint (no freedom from the composite endpoint). The absence of all 4 possible outcomes will be counted as Yes for freedom from all of the possible outcomes.


Secondary Outcome Measures :
  1. Proportion of subjects experiencing nephrotoxicity during the study [ Time Frame: 6 months ]
    Increase in serum creatinine of ≥0.3mg/dL

  2. Proportion of subjects experiencing neurotoxicity during the study [ Time Frame: 6 months ]
    Clinical intolerability including headache or significant tremors that resolve with reduction of the dose of Envarsus

  3. Proportion of subjects experiencing infectious complications during the study [ Time Frame: 6 months ]
    Participants requiring extended (>2 weeks) reduction in dose of Envarsus due to BK-polyomavirus or cytomegalovirus viral loads at 1, 3, and 6 months post-transplant

  4. Difference in estimated glomerular filtration rate at 1, 3, and 6 months between groups of enrolled subjects [ Time Frame: 6 months ]
    Assessed as the Chronic Kidney Disease - Epidemiology Collaboration equation

  5. Difference in immunosuppressant side effects between enrolled subjects [ Time Frame: 6 months ]
    Assessed using the "Immunosuppressant Side Effects Instrument - The Memphis Survey" questionnaire

  6. Enrolled subject overall survival and Graft survival at 6 months [ Time Frame: 6 months ]
    Freedom from death and from graft loss at 6 months



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • • Primary live donor or deceased donor renal allograft

    • African American patients aged 18 to 65 years
    • Ability to take oral medications
    • Not currently on medications known to significantly interfere with tacrolimus metabolism, e.g. strong CYP3A4 inducers or inhibitors including but not limited to rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital, protease inhibitors, azole antifungal (voriconazole, itraconazole, posaconazole, ketoconazole)

      o Note: All patients will be discharged on clotrimazole 10 mg three times daily for one month for thrush prophylaxis, a known mild-to-moderate CYP3A4 inhibitor

    • Female subjects of childbearing potential:

      • Not current pregnant
      • Agree not to try to become pregnant during the study period
      • Agree to consistently use two forms of highly effective birth control throughout the study period
    • Provision of signed and dated informed consent form
    • Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion Criteria:

  • • Presence of a positive T- or B-cell flow cytometry allogeneic crossmatch

    • Presence of pre-formed anti-human leukocyte antigen (HLA) donor-specific antibodies (DSAs)
    • Recipient of an ABO-incompatible organ
    • Receipt of a multi-organ or dual kidney transplant
    • Receipt of pediatric en bloc deceased donor kidneys
    • Receipt of deceased donor kidney with a kidney donor profile index (KDPI) greater than or equal to 85%
    • Has undergone desensitization, or received antibody removal, anti-B-cell, or anti-plasma cell therapy in the 90 days preceding the transplant
    • Planned initiation of antibody removal (i.e. plasmapheresis) within 7 days of the transplant procedure
    • Positive test for latent tuberculosis (TB) and has not previously received adequate anti-microbial therapy or would require TB prophylaxis after transplant
    • Uncontrolled concomitant infection that would not allow for targeting escalated tacrolimus trough concentrations, as deemed by prescriber
    • Known infection or seropositivity for hepatitis B virus (HBV, defined by positive HBsAg, anti-HBcAg, or positive viral load) or hepatitis C virus (HCV) with active viral load
    • Current malignancy
    • Use of an investigational study in the 30 days prior to the transplant procedure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04665310


Sponsors and Collaborators
The Methodist Hospital System
Veloxis Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Ahmed O Gaber, MD Houston Methodist Physicians Organization
Publications:

Layout table for additonal information
Responsible Party: Ahmed Osama Gaber, MD, Director, Houston Methodist J.C. Walter Jr. Transplant Center, The Methodist Hospital System
ClinicalTrials.gov Identifier: NCT04665310    
Other Study ID Numbers: Pro00018836
First Posted: December 11, 2020    Key Record Dates
Last Update Posted: December 11, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ahmed Osama Gaber, MD, The Methodist Hospital System:
Renal Transplant
Donor Specific Antibodies
African American
Acute Rejection of Renal Transplant
Kidney Transplant
End Stage Renal Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action